Literature DB >> 22871958

Evaluation of autoimmune safety signal in observational vaccine safety studies.

Chun Chao1, Steven J Jacobsen.   

Abstract

Autoimmune safety evaluation is an important component of post-licensure vaccine safety evaluation. Recently, we published the findings from a large observational safety study of the quadrivalent human papillomavirus vaccine in females. From this study, based on two large managed care organizations, we have obtained some empirical data that may prove useful for the design of future vaccine safety studies within a managed care environment. For autoimmune conditions, a major challenge in vaccine safety study is to determine true incident cases in relation to the timing of vaccination. We found expert case review of medical records an indispensable component for autoimmune safety studies based on electronic health records. Case identification should also be expanded to include the use of laboratory test results or other relevant measures in addition to the disease specific ICD-9 diagnosis codes, when applicable. Furthermore, we recommend the parallel use of both safety signal evaluation that involves pattern evaluation for conditions that are more common, and statistical comparisons for conditions that are rather rare. Finally, we recommend an accompanying vaccine uptake study to understand the potential selection bias and confounding in a given study population that should be addressed with data collection and analytical techniques.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22871958      PMCID: PMC3579911          DOI: 10.4161/hv.21268

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  4 in total

1.  Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine.

Authors:  C Chao; N P Klein; C M Velicer; L S Sy; J M Slezak; H Takhar; B Ackerson; T C Cheetham; J Hansen; K Deosaransingh; M Emery; K-L Liaw; S J Jacobsen
Journal:  J Intern Med       Date:  2011-11-15       Impact factor: 8.989

2.  Correlates for human papillomavirus vaccination of adolescent girls and young women in a managed care organization.

Authors:  Chun Chao; Christine Velicer; Jeff M Slezak; Steven J Jacobsen
Journal:  Am J Epidemiol       Date:  2010-01-04       Impact factor: 4.897

3.  Correlates for completion of 3-dose regimen of HPV vaccine in female members of a managed care organization.

Authors:  Chun Chao; Christine Velicer; Jeff M Slezak; Steven J Jacobsen
Journal:  Mayo Clin Proc       Date:  2009-10       Impact factor: 7.616

4.  An unmasking phenomenon in an observational post-licensure safety study of adolescent girls and young women.

Authors:  Steven J Jacobsen; Lina S Sy; Bradley K Ackerson; Chun R Chao; Jeff M Slezak; T Craig Cheetham; Harpreet S Takhar; Christine M Velicer; John Hansen; Nicola P Klein
Journal:  Vaccine       Date:  2012-05-11       Impact factor: 3.641

  4 in total
  3 in total

1.  Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study.

Authors:  Niklas Worm Andersson; Emilia Myrup Thiesson; Mona Vestergaard Laursen; Stine Hasling Mogensen; Jesper Kjær; Anders Hviid
Journal:  BMJ       Date:  2022-07-13

2.  Association between human papillomavirus vaccination and serious adverse events in South Korean adolescent girls: nationwide cohort study.

Authors:  Dongwon Yoon; Ji-Ho Lee; Hyesung Lee; Ju-Young Shin
Journal:  BMJ       Date:  2021-01-29

3.  Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study.

Authors:  Lisen Arnheim-Dahlström; Björn Pasternak; Henrik Svanström; Pär Sparén; Anders Hviid
Journal:  BMJ       Date:  2013-10-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.